An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03)
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Patritumab Deruxtecan (Primary) ; Pembrolizumab (Primary) ; Capecitabine; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Olaparib; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HERTHENA-Breast-03
- Sponsors Merck Sharp & Dohme
- 03 Feb 2025 New trial record